Partnering Overview

Theraclone collaborates with strategic development partners to create therapeutically important antibody products. We are actively seeking partners to help us discover, develop and commercialize therapeutics in the setting of oncology and infectious disease. Strategic partnerships can be structured on the basis of disease area(s), collaboration roles, degree of financial risk-sharing, and commercial territory.


For vaccine developers, the I-STAR technology can also be used to assess patients' immune response to new vaccines in the early stages of clinical testing through comprehensive analysis of the B cell repertoire.


Theraclone offers:

To date, we have formed strategic collaborations involving antibodies discovered using our I-STAR technology with Gilead, Pfizer, Zenyaku Kogyo and the International AIDS Vaccine Initiative to discover using novel antibodies for the treatment and prevention of disease.

Partner Logos